Development of a Core Outcome Set for Children Aged 1-18 Years with Gastroesophageal Reflux Disease.


Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
06 2022
Historique:
received: 15 10 2021
revised: 21 12 2021
accepted: 26 01 2022
pubmed: 6 2 2022
medline: 22 6 2022
entrez: 5 2 2022
Statut: ppublish

Résumé

To develop a core outcome set for clinical studies assessing gastroesophageal reflux disease (GERD) in children. This core outcome set was developed using a 2-round Delphi technique and adhering to the Outcome Measures in Rheumatology Initiative (OMERACT 2.0) recommendations. Healthcare professionals (HCPs) and (parents of) children (age 1-18 years) with a GERD diagnosis (ie, the presence of bothersome symptoms), listed up to 5 harmful and/or beneficial outcomes that they considered important in the treatment of GERD. Outcomes mentioned by more than 10% of participants were put forward and rated and prioritized by HCPs, parents, and children in a second round. Outcomes with the highest rank formed the draft core outcome set. The final core outcome set was created during an online consensus meeting between an expert panel. The first round was completed by 118 of 125 HCPs (94%), 146 of 146 parents (100%), and 69 of 70 children (99%). A total of 80 of 118 HCPs (68%), 130 of 140 parents (93%), and 77 children (100%) completed round 2. "Adequate relief," "evidence of esophagitis," "feeding difficulties," "heartburn (≥4 years)," "hematemesis," "regurgitation," "sleeping difficulties," "vomiting," and "adverse events" were included in the final core outcome set for GERD in children aged 1-18 years. We identified a total set of 9 core outcomes and suggest these outcomes to be minimally measured in clinical studies assessing GERD in children. Implementation of this core outcome set is likely to increase comparison between studies and may thus provide future recommendations to improve treatment of GERD in children.

Identifiants

pubmed: 35120989
pii: S0022-3476(22)00074-9
doi: 10.1016/j.jpeds.2022.01.043
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-134.e5

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Robyn Rexwinkel (R)

Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: r.rexwinkel@amsterdamumc.nl.

Vera W A van Berge Henegouwen (VWA)

Department of Pediatric Gastroenterology, Sydney Children's Hospital, School of Women's and Children's Health, University of New South Wales, Sydney, Australia.

Maartje M J Singendonk (MMJ)

Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Usha Krishnan (U)

Department of Pediatric Gastroenterology, Sydney Children's Hospital, School of Women's and Children's Health, University of New South Wales, Sydney, Australia.

Yvan VandenPlas (Y)

Vrije University Brussel (VUB), UZ Brussel, KidZ Health Castle, Brussels, Belgium.

Caterina Strisciuglio (C)

Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples, Italy.

Rachel Rosen (R)

Center for Motility and Functional Gastrointestinal Disorders, Division of Gastroenterology, Boston Children's Hospital, Boston, MA.

Arnaud Lalanne (A)

Division of Pediatric Gastroenterology, Hepatology and Nutrition, CHU Lille, University Lille, France.

Shaman Rajindrajith (S)

Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.

Marc A Benninga (MA)

Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Merit M Tabbers (MM)

Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH